XJZY(SZ:002332)2017-03-29 16:00Financial Performance - The company's operating revenue for 2016 was CNY 2,503,730,345.15, representing a 0.95% increase compared to CNY 2,480,246,153.64 in 2015[19] - The net profit attributable to shareholders for 2016 was CNY 146,186,888.11, a significant increase of 37.20% from CNY 106,551,038.95 in 2015[19] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 130,700,572.17, up 40.04% from CNY 93,328,404.12 in the previous year[19] - The basic earnings per share for 2016 was CNY 0.24, reflecting a 20.00% increase from CNY 0.20 in 2015[19] - The total assets at the end of 2016 amounted to CNY 3,620,740,691.12, which is a 5.29% increase from CNY 3,438,943,218.46 at the end of 2015[20] - The total net assets attributable to shareholders at the end of 2016 were CNY 2,225,427,631.07, an increase of 3.98% from CNY 2,140,207,332.50 at the end of 2015[20] - The company achieved a revenue of CNY 250,373.03 million, representing a year-on-year growth of 0.95%[45] - The total profit reached CNY 18,302.93 million, with a significant increase of 43.10% compared to the previous year[45] - The net profit attributable to shareholders was CNY 14,618.69 million, marking a year-on-year growth of 37.20%[45] Cash Flow and Financial Management - The net cash flow from operating activities for 2016 was CNY 155,905,554.91, a decrease of 21.89% compared to CNY 199,607,086.19 in 2015[19] - The company raised a total of RMB 88,146.34 million through a non-public offering of 98,708,111 shares at RMB 8.93 per share, with net proceeds of RMB 86,194.84 million after deducting fees[79] - As of the reporting period, the company has utilized RMB 8,621.19 million of the raised funds, which accounts for approximately 9.99% of the total[78] - The cumulative amount of raised funds used is RMB 52,676.15 million, representing 61.1% of the total[78] - The company has RMB 34,680.33 million of the raised funds remaining, which has not yet been utilized[78] - The company reported an interest income of RMB 828.47 million from temporarily stored funds in non-public offering accounts[78] - The company has a total of RMB 30,000 million in financial products as idle funds, which have been stored for over two years[78] Dividend Distribution - The profit distribution plan approved by the board is to distribute a cash dividend of CNY 1.00 per 10 shares, with no bonus shares issued[6] - The company distributed a cash dividend of 1.00 yuan per 10 shares, totaling 61,080,811.10 yuan for the year 2016, which represents 41.78% of the net profit attributable to ordinary shareholders[108] - A cash dividend of CNY 1.00 per 10 shares will be distributed, totaling CNY 61,080,811.1, based on a total share capital of 610,808,111 shares[113] Market and Industry Position - The main business focus is on the production and sales of steroid raw materials and formulations, with key products including corticosteroids and sex hormones[29][30] - The pharmaceutical industry in China is undergoing significant reforms, with policies aimed at improving industry standards and promoting innovation, which benefits the company's market position[33] - The company has maintained a stable domestic market for raw materials while expanding its international business to increase market share[32] - The company has established stable business relationships with over 100 domestic steroid drug formulation manufacturers[39] Research and Development - The company launched 3 new products and received 5 clinical approval documents in 2016, focusing on gynecology, respiratory, anesthesia, and dermatology[47] - The company completed the development of over 20 raw material drug projects and 12 formulation projects in various stages[47] - The company will accelerate the R&D of drugs in gynecology, anesthesia, and respiratory categories to meet market demand and enhance its product portfolio[96] - R&D investment amounted to ¥87,135,750.71, a slight increase of 0.74% compared to ¥86,496,266.50 in 2015[66] Risk Management - The company has identified several risks including industry policy risks and raw material price fluctuations, which may impact future performance[6] - The company faces risks from industry policy changes, raw material price fluctuations, and bidding price reductions, which could impact production and operational performance[102] - The company aims to mitigate risks associated with new drug development by improving its R&D system and internal approval processes[103] Corporate Governance and Management - The company has established a comprehensive corporate governance structure to protect shareholder and creditor rights[149] - The company emphasizes employee rights protection and has implemented various welfare measures, including an enterprise annuity plan[150] - The company has a structured management team with clear roles and responsibilities, ensuring effective operational oversight[183] - The company has improved its internal management and control systems, enhancing its governance level in accordance with relevant laws and regulations[196] Environmental Responsibility - The company invests in environmental protection and has established a leadership group for clean production and energy conservation[151] - The company has established wastewater treatment facilities with a design capacity of 2400 tons per day and air pollution control facilities capable of handling 60,000 cubic meters per hour, all operating normally[154] - The company has implemented a clean production strategy, focusing on pollution source analysis and reduction measures, which has led to stable operation of pollution control facilities[153] - The company's environmental protection facilities have a stable operation rate exceeding 95%, ensuring compliance with relevant pollution discharge requirements[153] Employee Management - The company employed a total of 3,866 staff, with 1,233 in production, 1,303 in sales, and 727 in technical roles[191] - The educational background of employees includes 5 with doctoral degrees, 102 with master's degrees, and 800 with bachelor's degrees[191] - The company has a remuneration policy aimed at providing competitive salaries and benefits to enhance employee motivation and corporate vitality[192] - The company has implemented a training plan focusing on knowledge, skills, and professional qualities to meet business development needs[193]